Pharmacologic Modification of Transperitoneal Movement of Water

Abstract

Investigations concerning the influence of pharmacologic agents on transperitoneal water movement are predominantly undertaken in the hope that their results can help in a restoration of net ultrafiltration (UF) volume toward normal in cases with declining UF during long-term dialysis treatment. Net UF volume represents the difference between net transcapillary UF and lymphatic absorption. The choice of a pharmacological agent for enhancing UF depends on the mechanisms responsible for net UF loss, which include: (a) early dissipation of the transperitoneal osmotic gradient; (b) decrease in the peritoneal surface area; (c) lymphomonokine overproduction; (d) enhanced lymphatic absorption; (e) high residual volumes left in the peritoneal cavity; or (f) a combination of these factors. Leakage of dialysate to the abdominal wall sometimes occurring in peritoneally dialysed patients (1), according to a definition of net UF volume, cannot be regarded as a true UF loss.